11 hours ago
DETROIT — His college career unfrozen by a judge, Orlando Lovejoy is headed to the frozen tundra.
Lovejoy, who starred for Detroit Mercy men's basketball the last two seasons, has committed to fellow Horizon League program Green Bay for his fifth and final season of eligibility.
Lovejoy was among hundreds of college athletes from the high-school class of 2022 who were granted a fifth season of eligibility through temporary restraining orders from judges across the country. The NCAA recently announced a five-year eligibility window, starting with the high-school class of 2023.
Lovejoy, 23, was one of the top point guards in the Horizon League the last two seasons, and in 2025-26, he was first-team all-league as he led the **** ans to within a whisker of the league tournament championship and an appearance in the NCAA Tournament. Lovejoy, a Detroit native, started all 31 games for Detroit Mercy in 2025-26, and was top 10 in the league in scoring (15.8 points), **** ists (3.7) and steals (1.6). He made free throws at an 89.2% clip.
Lovejoy spent his first two college seasons at Eastern Michigan, before transferring to Detroit Mercy after the school hired Mark Montgomery as head coach. He contemplated transferring after his first season at Detroit Mercy to capitalize on NIL opportunities, but he ultimately returned to the **** ans and led them to the Horizon League championship game, in which they led much of the game before falling to Wright State, 66-63.
#seasons
Lovejoy, who starred for Detroit Mercy men's basketball the last two seasons, has committed to fellow Horizon League program Green Bay for his fifth and final season of eligibility.
Lovejoy was among hundreds of college athletes from the high-school class of 2022 who were granted a fifth season of eligibility through temporary restraining orders from judges across the country. The NCAA recently announced a five-year eligibility window, starting with the high-school class of 2023.
Lovejoy, 23, was one of the top point guards in the Horizon League the last two seasons, and in 2025-26, he was first-team all-league as he led the **** ans to within a whisker of the league tournament championship and an appearance in the NCAA Tournament. Lovejoy, a Detroit native, started all 31 games for Detroit Mercy in 2025-26, and was top 10 in the league in scoring (15.8 points), **** ists (3.7) and steals (1.6). He made free throws at an 89.2% clip.
Lovejoy spent his first two college seasons at Eastern Michigan, before transferring to Detroit Mercy after the school hired Mark Montgomery as head coach. He contemplated transferring after his first season at Detroit Mercy to capitalize on NIL opportunities, but he ultimately returned to the **** ans and led them to the Horizon League championship game, in which they led much of the game before falling to Wright State, 66-63.
#seasons
12 hours ago
Horizon Technology Finance Corp., an affiliate of Monroe Capital, on September 10 said that the RoHo Capital Opportunity Fund LLC, a joint venture formed by Horizon and CR Financial Holdings, Inc., the holding company for Roth Capital Partners, LLC, has provided a $20-million senior credit facility to NeoVolta, Inc., with the ability to increase the facility to $30 million upon mutual agreement. An initial $20 million was funded at closing to support NeoVolta's continued growth.NeoVolta is an energy technology company focused on developing and manufacturing domestic battery energy storage systems (BESS). Together with its joint venture partner LONGi, NeoVolta is developing a 210,600-square-foot manufacturing facility in Pendergrass, Georgia, to produce BESS systems designed to meet U.S. domestic content and supply-chain requirements. The facility is expected to have an initial annual production capacity of up to 2 GWh, with the potential to scale to 8 GWh over time."Providing growth capital to innovative companies operating in attractive, high-growth markets is a core focus of RoHo's investment strategy," said Paul Seitz, chief investment officer of Horizon. "Formed by Horizon and Roth Capital, RoHo pairs Horizon's venture lending and structuring expertise with Roth's deep public markets relationships to deliver flexible growth capital to small- and micro-cap public companies. We are pleased to support NeoVolta's growth plans with a tailored financing solution and look forward to continuing to deploy capital through RoHo in support of innovative public companies pursuing significant market opportunities.""Horizon and Roth Capital bring valuable experience and a collaborative approach as we advance NeoVolta's domestic battery energy storage systems manufacturing platform," said Ardes Johnson, CEO of NeoVolta. "As we ramp our Georgia facility and pursue larger commercial and utility-scale opportunities, this relationship supports our ability to execute on our long-term growth strategy."Horizon Technology Finance Corp. is a specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S.Monroe Capital is a premier ****** et management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity.CR Financial Holdings, Inc., is a private hol
12 hours ago
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease.
Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in the overall population. The endpoint combined cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization requiring hospitalization. Complete results have not yet been presented.
Royalty Pharma plc (NASDAQ:RPRX) provided Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with $500 million in January 2023. The transaction allocated $150 million to pelacarsen royalties and $350 million to Spinraza royalties. The clinical failure shifts the financial focus from uncertain pelacarsen upside to recovery through Spinraza.
Royalty Pharma plc (NASDAQ:RPRX) acquired 25% of the Spinraza royalties received by Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) through 2027. That share increases to 45% in 2028 on Spinraza annual sales of up to $1.5 billion.
Following the HORIZON result, the Spinraza interest will revert after aggregate payments to Royalty Pharma plc (NASDAQ:RPRX) reach $550 million, equal to 1.1 times the original funding. Management expects the structure to recover the entire investment and generate a modest positive return despite the clinical failure.
#royalty #pharma #cardiovascular #horizon
Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in the overall population. The endpoint combined cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization requiring hospitalization. Complete results have not yet been presented.
Royalty Pharma plc (NASDAQ:RPRX) provided Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with $500 million in January 2023. The transaction allocated $150 million to pelacarsen royalties and $350 million to Spinraza royalties. The clinical failure shifts the financial focus from uncertain pelacarsen upside to recovery through Spinraza.
Royalty Pharma plc (NASDAQ:RPRX) acquired 25% of the Spinraza royalties received by Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) through 2027. That share increases to 45% in 2028 on Spinraza annual sales of up to $1.5 billion.
Following the HORIZON result, the Spinraza interest will revert after aggregate payments to Royalty Pharma plc (NASDAQ:RPRX) reach $550 million, equal to 1.1 times the original funding. Management expects the structure to recover the entire investment and generate a modest positive return despite the clinical failure.
#royalty #pharma #cardiovascular #horizon
16 hours ago
The Tennessee **** ans made the first somewhat surprising pick of the 2026 NFL Draft when they selected former Ohio State wide receiver Carnell Tate with the number four overall pick. With his first NFL game on the horizon, CBS Sports' Ryan Wilson believes he was worth the fourth overall pick for the **** ans.
Tate was drafted with the expectation that he can become a foundational piece of the offense and a long-term number one target for second-year quarterback Cam Ward. That might be a lot to ask from a rookie, but everything about the situation suggests the **** ans had a plan.
The biggest question surrounding the **** ans' selection was whether Tate's talent will eventually justify taking him fourth overall. Including Tate, only five wide receivers (six if you include Travis Hunter) have been selected in the top five of the NFL Draft since 2015.
Excluding Jacksonville Jaguars WR/CB Travis Hunter, former **** ans WR Corey Davis had the worst rookie season of those top five selections with 375 yards and 0 touchdowns. So, it made sense why **** ans fans, specifically, may have had concerns about the Tate selection.
However, a strong training camp has many anticipating his NFL regular-season debut. Tate doesn't need to immediately become one of the best receivers in the NFL for the pick to be successful, but Tennessee needs to see enough flashes to believe they have found a long-term offensive cornerstone.
#tate #draft
Tate was drafted with the expectation that he can become a foundational piece of the offense and a long-term number one target for second-year quarterback Cam Ward. That might be a lot to ask from a rookie, but everything about the situation suggests the **** ans had a plan.
The biggest question surrounding the **** ans' selection was whether Tate's talent will eventually justify taking him fourth overall. Including Tate, only five wide receivers (six if you include Travis Hunter) have been selected in the top five of the NFL Draft since 2015.
Excluding Jacksonville Jaguars WR/CB Travis Hunter, former **** ans WR Corey Davis had the worst rookie season of those top five selections with 375 yards and 0 touchdowns. So, it made sense why **** ans fans, specifically, may have had concerns about the Tate selection.
However, a strong training camp has many anticipating his NFL regular-season debut. Tate doesn't need to immediately become one of the best receivers in the NFL for the pick to be successful, but Tennessee needs to see enough flashes to believe they have found a long-term offensive cornerstone.
#tate #draft
22 hours ago
As we head into Gameweek 4 of the 2026/27 Fantasy Premier League season, making the right armband choice is critical for solidifying early-season rank gains.
With prime fixtures on the horizon – including heavy hitters facing vulnerable defenses and high-flying budget **** ets continuing to shock the league – selecting the right captain can make or break your weekend.
Here is a breakdown of the top GW4 FPL captaincy pick options to help you make the ultimate decision.
Despite playing away at Old Trafford in the Manchester derby, Erling Haaland remains the undisputed premier option among game week 4 FPL captain picks.
Manchester United's backline has looked shaky to start the campaign, surrendering six goals in their opening three league matches.
#league #captain
With prime fixtures on the horizon – including heavy hitters facing vulnerable defenses and high-flying budget **** ets continuing to shock the league – selecting the right captain can make or break your weekend.
Here is a breakdown of the top GW4 FPL captaincy pick options to help you make the ultimate decision.
Despite playing away at Old Trafford in the Manchester derby, Erling Haaland remains the undisputed premier option among game week 4 FPL captain picks.
Manchester United's backline has looked shaky to start the campaign, surrendering six goals in their opening three league matches.
#league #captain
23 hours ago
Former First Lady Michelle Obama brought striped style to the 2026 U.S. Open women's singles semifinals on Thursday night at the USTA Billie Jean King National Tennis Center in New York City.
Michelle Obama
Obama sported a red, white and dark-striped dress for the Grand Slam tennis tournament. The quasi-patriotic palette got contemporary edge from faded lines running through the red and dark navy stripes, which shifted between vertical and horizontal directions.
More from WWD
Gabrielle Union Brings Out Ferragamo's Trendiest Suede Mules to the 2026 U.S. Open
#former
Michelle Obama
Obama sported a red, white and dark-striped dress for the Grand Slam tennis tournament. The quasi-patriotic palette got contemporary edge from faded lines running through the red and dark navy stripes, which shifted between vertical and horizontal directions.
More from WWD
Gabrielle Union Brings Out Ferragamo's Trendiest Suede Mules to the 2026 U.S. Open
#former
1 day ago
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
1 day ago
On August 11, Humana Inc. (NYSE:HUM) announced that its Medicaid plan, Humana Healthy Horizons in Indiana, is collaborating with HealthStream, Inc. (NASDAQ:HSTM). The partnership expands access to workforce training for caregivers, aiming to recruit and retain talent in rural and underserved communities. While one provides healthcare coverage and the other builds the software to train healthcare workers, both companies are capitalizing on the industry's critical focus: solving caregiving shortages and optimizing healthcare delivery.
HealthStream emerges as the operationally cleaner, higher-growth performer, while Humana continues to navigate a more complex transition marked by regulatory and profitability pressures. Humana Inc. (NYSE:HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, with an Insurance segment GAAP benefit ratio of 91.2%. The company reaffirmed its full-year adjusted EPS guidance of at least $9.00 but lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36, reflecting non-cash adjustments and value creation charges. Although individual Medicare Advantage membership is expected to grow approximately 25% in 2026, lower Star Ratings remain a significant drag on profitability.
HealthStream, Inc. (NASDAQ:HSTM), meanwhile, delivered record Q2 2026 results, with revenue rising 12.5% year over year to $83.7 million. Operating income increased 41.4% to $8.3 million, while net income climbed 23.8% to $6.7 million, or $0.23 per diluted share. Adjusted EBITDA also increased 16.9% to $20.6 million. The company's debt-free balance sheet, supported by $66.7 million in cash and cash equivalents, further strengthens its financial flexibility. While Humana operates at substantially greater scale, HealthStream is demonstrating stronger operational leverage, margin expansion, and balance sheet flexibility.
Humana's bull case is supported by strong Medicare Advantage membership growth, with the company targeting a 25% increase in 2026, alongside strategic expansion of its CenterWell primary care business and state Medicaid footprint, including its recent Illinois win. These initiatives could strengthen its long-term recovery and expand its addressable market. However, the bear case centers on elevated medical benefit ratios, which reached 91.2% in Q2, as well as regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds. These factors could further squeeze margins and weigh on net earnings.
#healthcare #year
HealthStream emerges as the operationally cleaner, higher-growth performer, while Humana continues to navigate a more complex transition marked by regulatory and profitability pressures. Humana Inc. (NYSE:HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, with an Insurance segment GAAP benefit ratio of 91.2%. The company reaffirmed its full-year adjusted EPS guidance of at least $9.00 but lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36, reflecting non-cash adjustments and value creation charges. Although individual Medicare Advantage membership is expected to grow approximately 25% in 2026, lower Star Ratings remain a significant drag on profitability.
HealthStream, Inc. (NASDAQ:HSTM), meanwhile, delivered record Q2 2026 results, with revenue rising 12.5% year over year to $83.7 million. Operating income increased 41.4% to $8.3 million, while net income climbed 23.8% to $6.7 million, or $0.23 per diluted share. Adjusted EBITDA also increased 16.9% to $20.6 million. The company's debt-free balance sheet, supported by $66.7 million in cash and cash equivalents, further strengthens its financial flexibility. While Humana operates at substantially greater scale, HealthStream is demonstrating stronger operational leverage, margin expansion, and balance sheet flexibility.
Humana's bull case is supported by strong Medicare Advantage membership growth, with the company targeting a 25% increase in 2026, alongside strategic expansion of its CenterWell primary care business and state Medicaid footprint, including its recent Illinois win. These initiatives could strengthen its long-term recovery and expand its addressable market. However, the bear case centers on elevated medical benefit ratios, which reached 91.2% in Q2, as well as regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds. These factors could further squeeze margins and weigh on net earnings.
#healthcare #year
2 days ago
CVS Health (NYSE: CVS) dealt with significant headwinds after the COVID-19 pandemic. The company's financial results suffered as sales of coronavirus-related products (such as diagnostic tests) declined, while expenses in its insurance business rose substantially, resulting in lower profits and margins. However, CVS Health has done a good job of addressing those problems, and the stock has rebounded. Shares are up 31% over the past 12 months. Wall Street thinks there may be even more upside on the horizon. CVS Health's average price target is $116.04 (according to Yahoo! Finance), implying a meaningful 20% upside from current levels. Is now a great time to buy the stock?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Over the past 18 months (or so), CVS Health has implemented several initiatives that have helped improve its business. For instance, the company closed dozens of stores, many of which were unprofitable. The pharmacy chain specialist also scaled back its insurance division, notably by exiting the Affordable Care Act marketplace. The results have been pretty impressive. Consider the company's second-quarter results. CVS Health's revenue increased by a healthy 7.3% year over year to $106.1 billion.
Adjusted earnings per share were $2.58, 42.5% higher than the year-ago period. Note the improvement in CVS Health's healthcare benefits segment, which offers health insurance services. Operating expenses as a percentage of revenue declined slightly to 12.4%, down from 12.5% in the prior-year quarter, even as revenue grew 3.5% year over year. And operating margins within this unit came in at 5.8%, up from the 2.8% reported in the year-ago period. Also, CVS Health's medical benefits ratio -- the percentage of insurance premiums the company spent on medical care (the lower the better) -- declined to 87.4% in the second quarter, down from 89.9% in Q2 2025.
CVS Health also increased its guidance for the full fiscal year 2026. The company now expects its adjusted EPS to fall between $7.90 and $8.10, up from its previous range of between $7.30 to $7.50. The company is also now projecting cash flow from operations of at least $11.5 billion, up from the previous lower bound of $9.5 billion. These are signs of a much-improved business.
#insurance
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Over the past 18 months (or so), CVS Health has implemented several initiatives that have helped improve its business. For instance, the company closed dozens of stores, many of which were unprofitable. The pharmacy chain specialist also scaled back its insurance division, notably by exiting the Affordable Care Act marketplace. The results have been pretty impressive. Consider the company's second-quarter results. CVS Health's revenue increased by a healthy 7.3% year over year to $106.1 billion.
Adjusted earnings per share were $2.58, 42.5% higher than the year-ago period. Note the improvement in CVS Health's healthcare benefits segment, which offers health insurance services. Operating expenses as a percentage of revenue declined slightly to 12.4%, down from 12.5% in the prior-year quarter, even as revenue grew 3.5% year over year. And operating margins within this unit came in at 5.8%, up from the 2.8% reported in the year-ago period. Also, CVS Health's medical benefits ratio -- the percentage of insurance premiums the company spent on medical care (the lower the better) -- declined to 87.4% in the second quarter, down from 89.9% in Q2 2025.
CVS Health also increased its guidance for the full fiscal year 2026. The company now expects its adjusted EPS to fall between $7.90 and $8.10, up from its previous range of between $7.30 to $7.50. The company is also now projecting cash flow from operations of at least $11.5 billion, up from the previous lower bound of $9.5 billion. These are signs of a much-improved business.
#insurance
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
2 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Gold (GC=F) December futures opened at $4,399 per troy ounce on Wednesday, September 9, 2026, down 0.9% from Tuesday's closing price. Gold moved back higher in early trading this morning to $4,438.20 per troy ounce as of 6:34 a.m. ET.
Exactly one week ago, our headline here was "Gold slips further as military actions escalate in Iran." And that's exactly the headline news yet again.
Oil prices (BZ=F) are currently over $100 a barrel, as gold opens at its lowest value in a week, following reports that the U.S. military destroyed five more Iranian oil tankers in response to Iranian attacks on U.S. warships:
U.S. Central Command (Centcom) announced late on Tuesday that American forces had destroyed five Iranian crude oil carriers, once again claiming that it was in response to the IRGC targeting a U.S. Navy warship with ballistic missiles. Four of the carriers, M/T Kaviz, M/T Charminar, M/T Horizon 1, and M/T Riesco, were destroyed in the Gulf of Oman. One of the carriers, M/T Derya, was struck near Kharg Island.
#Gold #military
Gold (GC=F) December futures opened at $4,399 per troy ounce on Wednesday, September 9, 2026, down 0.9% from Tuesday's closing price. Gold moved back higher in early trading this morning to $4,438.20 per troy ounce as of 6:34 a.m. ET.
Exactly one week ago, our headline here was "Gold slips further as military actions escalate in Iran." And that's exactly the headline news yet again.
Oil prices (BZ=F) are currently over $100 a barrel, as gold opens at its lowest value in a week, following reports that the U.S. military destroyed five more Iranian oil tankers in response to Iranian attacks on U.S. warships:
U.S. Central Command (Centcom) announced late on Tuesday that American forces had destroyed five Iranian crude oil carriers, once again claiming that it was in response to the IRGC targeting a U.S. Navy warship with ballistic missiles. Four of the carriers, M/T Kaviz, M/T Charminar, M/T Horizon 1, and M/T Riesco, were destroyed in the Gulf of Oman. One of the carriers, M/T Derya, was struck near Kharg Island.
#Gold #military
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
2 days ago
Northern Kentucky University's men's basketball program announced its full slate of non-conference games with the Norse set to host five games at Truist Arena.
Northern Kentucky opens the 2026-27 season in Sioux Falls, South Dakota, taking on UTEP as part of the Field of 68 Opening Day Marathon. The Norse will stay in the Mount Rushmore State for a matchup with South Dakota on Nov. 4. As previously announced, NKU then heads to College Station, taking on Texas A&M on Nov. 6. It marks the first time the Norse have played Texas A&M since the 2017-18 campaign. Northern Kentucky wraps up its four-game road trip to open the season at Chaifetz Arena, where they'll take on Saint Louis on Nov. 10.
Both Texas A&M and Saint Louis reached the second round of the NCAA Tournament last season.
Then, the Norse start a four-game homestand leading into Thanksgiving, opening their home schedule on Nov. 14 against Central Michigan. Last season, NKU beat the Chippewas by 24 in Mount Pleasant. Northern Kentucky will then host Georgia Southern on Nov. 23 and Bellarmine on Nov. 25 as part of a a multi-team event with those teams playing each other at Truist Arena Nov. 24. Northern Kentucky's matchup with Georgia Southern will be the first in program history, while this season's matchup vs. Bellarmine marks the 80th all-time, with the Norse leading the series 45-34.
NKU has four out-of-conference games in December, taking on Defiance on Dec. 8, before facing South Carolina State on Dec. 11, both at Truist Arena. The Norse wrap up their non-Horizon League schedule by taking on ETSU in Johnson City on Dec. 15, before traveling up to Cambridge, Massachusetts, to take on Harvard on Dec. 20. It'll mark the first time that the Norse and Crimson have faced off, while the Norse traveled to ETSU last season.
#taking #texas
Northern Kentucky opens the 2026-27 season in Sioux Falls, South Dakota, taking on UTEP as part of the Field of 68 Opening Day Marathon. The Norse will stay in the Mount Rushmore State for a matchup with South Dakota on Nov. 4. As previously announced, NKU then heads to College Station, taking on Texas A&M on Nov. 6. It marks the first time the Norse have played Texas A&M since the 2017-18 campaign. Northern Kentucky wraps up its four-game road trip to open the season at Chaifetz Arena, where they'll take on Saint Louis on Nov. 10.
Both Texas A&M and Saint Louis reached the second round of the NCAA Tournament last season.
Then, the Norse start a four-game homestand leading into Thanksgiving, opening their home schedule on Nov. 14 against Central Michigan. Last season, NKU beat the Chippewas by 24 in Mount Pleasant. Northern Kentucky will then host Georgia Southern on Nov. 23 and Bellarmine on Nov. 25 as part of a a multi-team event with those teams playing each other at Truist Arena Nov. 24. Northern Kentucky's matchup with Georgia Southern will be the first in program history, while this season's matchup vs. Bellarmine marks the 80th all-time, with the Norse leading the series 45-34.
NKU has four out-of-conference games in December, taking on Defiance on Dec. 8, before facing South Carolina State on Dec. 11, both at Truist Arena. The Norse wrap up their non-Horizon League schedule by taking on ETSU in Johnson City on Dec. 15, before traveling up to Cambridge, Massachusetts, to take on Harvard on Dec. 20. It'll mark the first time that the Norse and Crimson have faced off, while the Norse traveled to ETSU last season.
#taking #texas
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
6 days ago
The summer window may have just closed, but Barcelona are already planning for January, with a significant financial decision looming on the horizon.
The club have approximately €60 million available in their Financial Fair Play allocation, giving them room to manoeuvre in the winter market should they choose to.
However, that money could also serve a very different purpose, particularly for the season ahead.
Barcelona bosses have a decision to make. (Photo by Alex Caparros/Getty Images)
According to Diario SPORT, Barcelona face a clear choice with their available FFP funds.
#caparros
The club have approximately €60 million available in their Financial Fair Play allocation, giving them room to manoeuvre in the winter market should they choose to.
However, that money could also serve a very different purpose, particularly for the season ahead.
Barcelona bosses have a decision to make. (Photo by Alex Caparros/Getty Images)
According to Diario SPORT, Barcelona face a clear choice with their available FFP funds.
#caparros
7 days ago
On a cold November morning, designer Isaac Mizrahi gets up, leaves his apartment, and trudges to the corner newsstand to pick up a copy of Women's Wear Daily. It's the day after Mizrahi's Spring/Summer 1994 show, and the ink on the reviews is still wet. Reading from the pages, he quotes, "'His usually great color sense failed him, his fabric sense failed him, and certainly, his sense of how a modern woman dresses after 8 p.m. failed him." The verdict is withering. Mizrahi, one of the great artists of '90s ready-to-wear fashion, has been tossed out. Disgraced. Lightly "cancelled," as some might call it these days.
Douglas Keeve's sublime 1995 documentary, "Unzipped," follows Mizrahi in the aftermath of a train wreck, piecing his reputation back together with his next collection, attempting to make something beautiful from the rubble. We find Mizrahi's world in grayscale, drained of color in the wake of critical and cultural failure. Then, the opening notes of Sandra Bernhard's 1994 cover of Sylvester's "You Make Me Feel (Mighty Real)" cue the pigmentation, cascading over bright images of models in fittings, garments hanging from racks, and plenty of DayGlo faux furs. In her version, Bernhard alters the lyrics to pay tribute to Sylvester, whose untimely death left an immense legacy. "Sylvester, sister," Bernhard coos, "You were so beautiful, you were so fragile, you were so . . . real."
But just before Bernhard finishes the word, the song fades to silence, as if to say that realness — genuine authenticity in your life and work, at the cost of criticism — will always be snuffed out before it can be fully appreciated. That is the price of beauty. What is up must always come down.
(Janus Films) Isaac Mizrahi in "Unzipped"
After years in cinematic obscurity — the film hasn't been readily available outside of the eBay market in decades — "Unzipped" will return to theaters later this month, with a loving 4K restoration from Janus Films, just as another fashion-world controversy is heating up. Earlier this week, the Metropolitan Museum of Art declared it would no longer proceed with its Costume Institute's upcoming exhibition honoring John Galliano, scheduled to debut next year. When the scrapped "John Galliano: Horizons" was announced in July, the exhibition was immediately met with an outpouring of criticism. Detractors accused the museum of being tone deaf, citing a 2011 video of Galliano going on a drunken antisemitic and racist rant at a Paris bar, for which Galliano was promptly ousted from his spot as creative director at Dior. Following the video surfacing, Galliano apologized, went to rehab, and, over the last few years, experienced a brand resurgence that some would call a whitewashing.
#mizrahi #bernhard #sense
Douglas Keeve's sublime 1995 documentary, "Unzipped," follows Mizrahi in the aftermath of a train wreck, piecing his reputation back together with his next collection, attempting to make something beautiful from the rubble. We find Mizrahi's world in grayscale, drained of color in the wake of critical and cultural failure. Then, the opening notes of Sandra Bernhard's 1994 cover of Sylvester's "You Make Me Feel (Mighty Real)" cue the pigmentation, cascading over bright images of models in fittings, garments hanging from racks, and plenty of DayGlo faux furs. In her version, Bernhard alters the lyrics to pay tribute to Sylvester, whose untimely death left an immense legacy. "Sylvester, sister," Bernhard coos, "You were so beautiful, you were so fragile, you were so . . . real."
But just before Bernhard finishes the word, the song fades to silence, as if to say that realness — genuine authenticity in your life and work, at the cost of criticism — will always be snuffed out before it can be fully appreciated. That is the price of beauty. What is up must always come down.
(Janus Films) Isaac Mizrahi in "Unzipped"
After years in cinematic obscurity — the film hasn't been readily available outside of the eBay market in decades — "Unzipped" will return to theaters later this month, with a loving 4K restoration from Janus Films, just as another fashion-world controversy is heating up. Earlier this week, the Metropolitan Museum of Art declared it would no longer proceed with its Costume Institute's upcoming exhibition honoring John Galliano, scheduled to debut next year. When the scrapped "John Galliano: Horizons" was announced in July, the exhibition was immediately met with an outpouring of criticism. Detractors accused the museum of being tone deaf, citing a 2011 video of Galliano going on a drunken antisemitic and racist rant at a Paris bar, for which Galliano was promptly ousted from his spot as creative director at Dior. Following the video surfacing, Galliano apologized, went to rehab, and, over the last few years, experienced a brand resurgence that some would call a whitewashing.
#mizrahi #bernhard #sense
7 days ago
John Galliano has canceled his Metropolitan Museum of Art exhibit, saying in a statement shared Monday (Aug. 31) that he remains "fully accountable for the pain caused by my words in the past."
In the statement, which comes amid mounting criticism against the designer, Galliano expressed gratitude to Anna Wintour and others involved with staging the exhibit, but conceded that the planned project should not move forward.
"After much reflection and discussion with all those involved, I have decided, with great sadness, that it is best for the exhibition not to take place at this time," Galliano said Monday, in part. "I remain fully accountable for the pain caused by my words in the past, particularly the hurt I caused to the Jewish and Asian communities, and I remain deeply sorry. I understand that meaningful atonement is not achieved through an exhibition, institutional recognition, or a single public gesture. It is a continuing responsibility, demonstrated through listening, learning, and one's conduct over time."
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
The planned exhibition, ******* led John Galliano: Horizons, had previously been slated to open in May of next year. In addition to Galliano's personal statement, Max Hollein, who serves as director and CEO of the Metropolitan Museum of Art, also shared a confirmation of the cancelation.
#galliano
In the statement, which comes amid mounting criticism against the designer, Galliano expressed gratitude to Anna Wintour and others involved with staging the exhibit, but conceded that the planned project should not move forward.
"After much reflection and discussion with all those involved, I have decided, with great sadness, that it is best for the exhibition not to take place at this time," Galliano said Monday, in part. "I remain fully accountable for the pain caused by my words in the past, particularly the hurt I caused to the Jewish and Asian communities, and I remain deeply sorry. I understand that meaningful atonement is not achieved through an exhibition, institutional recognition, or a single public gesture. It is a continuing responsibility, demonstrated through listening, learning, and one's conduct over time."
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
The planned exhibition, ******* led John Galliano: Horizons, had previously been slated to open in May of next year. In addition to Galliano's personal statement, Max Hollein, who serves as director and CEO of the Metropolitan Museum of Art, also shared a confirmation of the cancelation.
#galliano
7 days ago
Ameresco insiders have been buying into a steep decline instead of waiting for the chart to improve. Form 4 filings show open-market purchases of roughly $1.9 million since August 7, including about $738,000 over the latest one-week sequence. CEO George Sakellaris accounted for approximately $574,000 across several purchases. Directors Brian ***** , Jennifer Miller, and Joseph Sutton also bought shares of Ameresco, Inc. (NYSE:AMRC). The cluster spread the bullish signal across four insiders rather than one executive.
The timing is interesting because the stock had fallen about 28% over six months. Ameresco develops energy infrastructure, including efficiency projects, renewable ***** ets, battery storage, and power systems that can support data centers. Its opportunity is not to predict which AI model wins. It is to help customers build the electricity and resilience those models require. Second-quarter revenue rose 9.1% to $515.5 million, showing that the operating business was still expanding during the selloff.
Insider buying is a useful signal, but it is not a guarantee. Executives may have long time horizons, personal tax considerations, or confidence that does not translate into near-term returns. Ameresco's projects carry construction, financing, customer-concentration, and execution risk. Diluted EPS of $0.18 fell 25% year over year in Q2, demonstrating that higher revenue does not automatically deliver better profitability. Large AI-related power awards can also produce uneven working-capital needs before cash arrives.
The hedge-fund picture was weaker than the insider activity. Insider Monkey tracked 17 hedge funds holding Ameresco, Inc. (NYSE:AMRC) in Q2, down from 22 in Q1. Millennium Management sharply increased its position by 490% to 1,487,282 shares, however, making the quarter more nuanced than the falling holder count suggests. One large buyer can coexist with broad caution.
Short positioning reinforces that caution. At the August 14 settlement, 4.51 million shares were sold short, equal to about 15% of the reported float and 5.36 days of average volume. The insider cluster suggests people closest to the company see value after the decline. A durable rebound still requires Ameresco to turn AI-power demand and project awards into margins, cash flow, and a balance sheet investors can underwrite without heroic ***** umptions.
#shares #power #august #amrc
The timing is interesting because the stock had fallen about 28% over six months. Ameresco develops energy infrastructure, including efficiency projects, renewable ***** ets, battery storage, and power systems that can support data centers. Its opportunity is not to predict which AI model wins. It is to help customers build the electricity and resilience those models require. Second-quarter revenue rose 9.1% to $515.5 million, showing that the operating business was still expanding during the selloff.
Insider buying is a useful signal, but it is not a guarantee. Executives may have long time horizons, personal tax considerations, or confidence that does not translate into near-term returns. Ameresco's projects carry construction, financing, customer-concentration, and execution risk. Diluted EPS of $0.18 fell 25% year over year in Q2, demonstrating that higher revenue does not automatically deliver better profitability. Large AI-related power awards can also produce uneven working-capital needs before cash arrives.
The hedge-fund picture was weaker than the insider activity. Insider Monkey tracked 17 hedge funds holding Ameresco, Inc. (NYSE:AMRC) in Q2, down from 22 in Q1. Millennium Management sharply increased its position by 490% to 1,487,282 shares, however, making the quarter more nuanced than the falling holder count suggests. One large buyer can coexist with broad caution.
Short positioning reinforces that caution. At the August 14 settlement, 4.51 million shares were sold short, equal to about 15% of the reported float and 5.36 days of average volume. The insider cluster suggests people closest to the company see value after the decline. A durable rebound still requires Ameresco to turn AI-power demand and project awards into margins, cash flow, and a balance sheet investors can underwrite without heroic ***** umptions.
#shares #power #august #amrc
8 days ago
Pfizer (NYSE: PFE) has faced several issues in recent years that have weighed on its share price. First, the company's coronavirus business isn't nearly as strong as it once was. Second, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant. Third, the pharmaceutical giant has faced clinical setbacks with otherwise promising pipeline candidates, including some it acquired. This problem has led to billions in impairment charges. Because of these headwinds (and others), Pfizer's shares have lagged broader equities over the past two years and have hovered below $30 apiece. Is it finally time to invest in the company? Let's see whether there is a rebound on the horizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's start with Pfizer's recent second-quarter update. The company's revenue increased by 1% year over year to $15 billion. While that top-line growth doesn't look impressive, it beat ***** yst estimates. On the bottom line, Pfizer's adjusted earnings per share were $0.77, slightly lower than the $0.78 reported in the prior-year quarter. Here too, Pfizer beat expectations. And it's important to highlight what drove the revenue and earnings beat.
The company noted that non-COVID revenue increased 5% year over year, while sales from launched and acquired products jumped 18%. This is great news for Pfizer. It suggests that newer (and acquired) products will help pull sales in the right direction over the medium term, while older medicines, especially within its coronavirus business, continue to lose steam.
Even with the progress Pfizer is making with relatively new launches, upcoming patent cliffs will be a major problem for the company. Consider, for instance, that Eliquis was the drugmaker's best-selling therapy during the second quarter. Pfizer's revenue from Eliquis came in at $2.4 billion, up 21% year over year. So, it arguably remains its single most important growth driver. Pfizer will have to launch more new drugs to fill the gap Eliquis will leave behind as it faces generic competition by the end of the decade. Can the company pull it off? My view is that it can.
#company #revenue #years
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's start with Pfizer's recent second-quarter update. The company's revenue increased by 1% year over year to $15 billion. While that top-line growth doesn't look impressive, it beat ***** yst estimates. On the bottom line, Pfizer's adjusted earnings per share were $0.77, slightly lower than the $0.78 reported in the prior-year quarter. Here too, Pfizer beat expectations. And it's important to highlight what drove the revenue and earnings beat.
The company noted that non-COVID revenue increased 5% year over year, while sales from launched and acquired products jumped 18%. This is great news for Pfizer. It suggests that newer (and acquired) products will help pull sales in the right direction over the medium term, while older medicines, especially within its coronavirus business, continue to lose steam.
Even with the progress Pfizer is making with relatively new launches, upcoming patent cliffs will be a major problem for the company. Consider, for instance, that Eliquis was the drugmaker's best-selling therapy during the second quarter. Pfizer's revenue from Eliquis came in at $2.4 billion, up 21% year over year. So, it arguably remains its single most important growth driver. Pfizer will have to launch more new drugs to fill the gap Eliquis will leave behind as it faces generic competition by the end of the decade. Can the company pull it off? My view is that it can.
#company #revenue #years
8 days ago
This story was originally published on Banking Dive. To receive daily news and insights, subscribe to our free daily Banking Dive newsletter.
TD's aim to open 100 U.S. branches by 2028 is "a today strategy," not simply a revival of branch expansion plans shared in 2023, U.S. executive Allison Robinson said Wednesday.
The Canadian bank said last week it intends to open 100 branches in the U.S. by the end of 2028, as it purses organic growth. The lender also plans to hire more retail and commercial bankers, U.S. CEO Leo Salom said during the bank's fiscal third-quarter earnings call Aug. 27.
In May 2023, Toronto-based TD shared plans to open 150 U.S. branches by 2027, with a focus on the Southeast – just a few weeks after its proposed $13.4 billion acquisition of Memphis, Tennessee-based First Horizon was terminated. At the time, TD circled south Florida, Atlanta and North Carolina as targeted areas for branch expansion.
But as the bank tackled anti-money laundering issues and was hit with a related $3.09 billion penalty and $434 billion ******* et cap on U.S. retail operations, those branch opening plans slowed "dramatically," then-CEO Bharat Masrani acknowledged in 2024. TD has also closed about 91 branches over the past two years, Salom said last week.
#dive
TD's aim to open 100 U.S. branches by 2028 is "a today strategy," not simply a revival of branch expansion plans shared in 2023, U.S. executive Allison Robinson said Wednesday.
The Canadian bank said last week it intends to open 100 branches in the U.S. by the end of 2028, as it purses organic growth. The lender also plans to hire more retail and commercial bankers, U.S. CEO Leo Salom said during the bank's fiscal third-quarter earnings call Aug. 27.
In May 2023, Toronto-based TD shared plans to open 150 U.S. branches by 2027, with a focus on the Southeast – just a few weeks after its proposed $13.4 billion acquisition of Memphis, Tennessee-based First Horizon was terminated. At the time, TD circled south Florida, Atlanta and North Carolina as targeted areas for branch expansion.
But as the bank tackled anti-money laundering issues and was hit with a related $3.09 billion penalty and $434 billion ******* et cap on U.S. retail operations, those branch opening plans slowed "dramatically," then-CEO Bharat Masrani acknowledged in 2024. TD has also closed about 91 branches over the past two years, Salom said last week.
#dive
8 days ago
USA Rare Earth (NASDAQ: USAR) is a critical minerals specialist that went public through a merger with special purpose acquisition company (SPAC) Inflection Point Acquisition Corp. II in March 2025. The company saw some volatile trading in the months immediately following its debut, but it went on to hit a lifetime high in October of that year following reports that the company was discussing a potential partnership with the White House and rumors that the U.S. government could take a stake in the business.
In January 2026, USA Rare Earth actually did announce that the U.S. government was establishing a roughly 10% ownership stake in the company that could expand to 16% with the exercise of warrants -- but its share price has still fallen far below the high it hit last year. As of this writing, the stock is down roughly 53.5% from that valuation peak. In other words, a $10,000 investment made in the stock at that point would now be worth roughly $4,650.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
While the U.S. government's desire to increase its ability to source critical minerals domestically and reduce its dependence on minerals from China presents a potentially powerful catalyst for USA Rare Earth's business, the company is still in a relatively early stage of expanding its operations. Along those lines, the company generated just $11.5 million in revenue across the first half of this year. Meanwhile, the mining and processing player has a market capitalization of roughly $4.4 billion.
The company's move to acquire Brazilian rare-earth specialist Serra Verde in a roughly $2.8 billion deal should dramatically expand USA Rare Earth's sales footprint and earnings potential, but the deal being primarily funded with stock also means that shareholders will see significant dilution. USA Rare Earth has growth opportunities on the horizon that could help it bounce back and climb well above its past valuation peak, but investors should approach the stock with the understanding that it's a speculative bet.
#rare #roughly #NVIDIA #year
In January 2026, USA Rare Earth actually did announce that the U.S. government was establishing a roughly 10% ownership stake in the company that could expand to 16% with the exercise of warrants -- but its share price has still fallen far below the high it hit last year. As of this writing, the stock is down roughly 53.5% from that valuation peak. In other words, a $10,000 investment made in the stock at that point would now be worth roughly $4,650.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
While the U.S. government's desire to increase its ability to source critical minerals domestically and reduce its dependence on minerals from China presents a potentially powerful catalyst for USA Rare Earth's business, the company is still in a relatively early stage of expanding its operations. Along those lines, the company generated just $11.5 million in revenue across the first half of this year. Meanwhile, the mining and processing player has a market capitalization of roughly $4.4 billion.
The company's move to acquire Brazilian rare-earth specialist Serra Verde in a roughly $2.8 billion deal should dramatically expand USA Rare Earth's sales footprint and earnings potential, but the deal being primarily funded with stock also means that shareholders will see significant dilution. USA Rare Earth has growth opportunities on the horizon that could help it bounce back and climb well above its past valuation peak, but investors should approach the stock with the understanding that it's a speculative bet.
#rare #roughly #NVIDIA #year
9 days ago
Football season is on the horizon, and for the Oklahoma Sooners, it starts on a Friday.
Norman Public Schools and the University of Oklahoma already announced in-person class closures for that day due to expected heavy traffic, so it's safe to say anyone going to the game may want to plan ahead.
OU released a new game day driving maps and recommended protocols to improve traffic flow in Norman, particularly around the stadium. The map was developed alongside the Norman and OU police departments.
The map shows preferred routes to multiple parking lots and road closures.
Here is what OU recommends fans do to avoid delays and reduce stress.
#closures #schools
Norman Public Schools and the University of Oklahoma already announced in-person class closures for that day due to expected heavy traffic, so it's safe to say anyone going to the game may want to plan ahead.
OU released a new game day driving maps and recommended protocols to improve traffic flow in Norman, particularly around the stadium. The map was developed alongside the Norman and OU police departments.
The map shows preferred routes to multiple parking lots and road closures.
Here is what OU recommends fans do to avoid delays and reduce stress.
#closures #schools
9 days ago
Paddy Donovan insists he is not "underestimating" Tyrone McKenna before they meet at Croke Park on Saturday with a second crack at world honours on the horizon.
Donovan bounced back from his first ******* le defeat by Lewis Crocker with an impressive victory over Karen Chukhadzhian in May to return to the mandatory slot for the IBF welterweight ******* le held by Australia's Liam Paro.
The Limerick man is aware of the risks in taking a fight in the interim, but felt this was too good an opportunity to turn down and plans to put on a show to elevate his status.
He and McKenna have sparred countless rounds over the years and the 27-year-old, whose record is 15 wins with two defeats, feels he is a level above his fellow southpaw.
"It's risky to take the fight being number one with the IBF but I couldn't turn down the opportunity to fight in front of 80,000 Irish fans," Donovan said at Thursday's news conference.
#title #Opportunity #tyrone
Donovan bounced back from his first ******* le defeat by Lewis Crocker with an impressive victory over Karen Chukhadzhian in May to return to the mandatory slot for the IBF welterweight ******* le held by Australia's Liam Paro.
The Limerick man is aware of the risks in taking a fight in the interim, but felt this was too good an opportunity to turn down and plans to put on a show to elevate his status.
He and McKenna have sparred countless rounds over the years and the 27-year-old, whose record is 15 wins with two defeats, feels he is a level above his fellow southpaw.
"It's risky to take the fight being number one with the IBF but I couldn't turn down the opportunity to fight in front of 80,000 Irish fans," Donovan said at Thursday's news conference.
#title #Opportunity #tyrone
9 days ago
With the first two matchdays of the league season behind us and the summer transfer window now closed, Serie A teams are back at work. Summer is now over, with coaches, staff, and players on the pitch preparing for the next fixtures.
Watch the full Serie BKT live with LaB Channel on OneFootball: subscribe for just €9.99 a month!
The weekend is just around the corner, and on the horizon there is a clash between two Scudetto contenders: on Saturday, Inter vs Napoli will take place at San Siro at 6 PM. But that's not all: Serie A's third round will also bring two other high-stakes matches, Roma vs Atalanta and Juventus vs Milan.
Here we look at today's biggest stories.
Edon Zhegrova remains at the center of a delicate situation. The Kosovan has been left out of the UEFA squad submitted by Juventus and, according to Corriere dello Sport, could leave Turin to move to Saudi Arabia.
#serie #watch
Watch the full Serie BKT live with LaB Channel on OneFootball: subscribe for just €9.99 a month!
The weekend is just around the corner, and on the horizon there is a clash between two Scudetto contenders: on Saturday, Inter vs Napoli will take place at San Siro at 6 PM. But that's not all: Serie A's third round will also bring two other high-stakes matches, Roma vs Atalanta and Juventus vs Milan.
Here we look at today's biggest stories.
Edon Zhegrova remains at the center of a delicate situation. The Kosovan has been left out of the UEFA squad submitted by Juventus and, according to Corriere dello Sport, could leave Turin to move to Saudi Arabia.
#serie #watch
9 days ago
A possible family conversation could be on the horizon for Prince Harry and Kate Middleton. However, the Princess of Wales is reportedly determined not to put herself against Prince William. It is speculated that Harry's return to the UK could bring him into closer contact with the family after years of separation. Now, a source claims the Duke of Sussex sees Middleton as someone who could help reopen a line of communication.
Prince Harry is allegedly hoping to reconnect with Kate Middleton as he settles into spending more time in the UK. According to a source cited by Closer Online, he sees her as someone who may be more willing to listen. With Prince William still apparently unwilling to speak with him, Harry could turn to Middleton as a possible bridge.
The timing is significant. Harry and Meghan Markle have returned to Britain with their children, Prince Archie and Princess Lilibet, after six years away in California. The family is said to be establishing a longer-term presence in the country. That could make future encounters with the wider Royal Family more likely.
For years, Harry and William have largely kept their distance. Their strained relationship has continued despite the "Spare" author making efforts to improve his bond with his father, King Charles. Now, with Harry back in the UK, avoiding each other could become increasingly difficult.
That is reportedly why Harry wants to approach Middleton. A source claims he sees her as a "more reasonable" person who could help maintain a line of communication. Still, the insider acknowledges that putting her in the middle would be uncomfortable.
#harry #middleton #source #princess
Prince Harry is allegedly hoping to reconnect with Kate Middleton as he settles into spending more time in the UK. According to a source cited by Closer Online, he sees her as someone who may be more willing to listen. With Prince William still apparently unwilling to speak with him, Harry could turn to Middleton as a possible bridge.
The timing is significant. Harry and Meghan Markle have returned to Britain with their children, Prince Archie and Princess Lilibet, after six years away in California. The family is said to be establishing a longer-term presence in the country. That could make future encounters with the wider Royal Family more likely.
For years, Harry and William have largely kept their distance. Their strained relationship has continued despite the "Spare" author making efforts to improve his bond with his father, King Charles. Now, with Harry back in the UK, avoiding each other could become increasingly difficult.
That is reportedly why Harry wants to approach Middleton. A source claims he sees her as a "more reasonable" person who could help maintain a line of communication. Still, the insider acknowledges that putting her in the middle would be uncomfortable.
#harry #middleton #source #princess
10 days ago
Michigan women's basketball guard Brooke Quarles Daniels had an excellent journey in her four years of college basketball.
The 5-foot-7 guard from Macomb, Mich. played two years at Oakland, averaging 12.8 points, 2.9 ****** ists and 2.2 steals per game while named to the All-Horizon League Second Team twice, as Freshman of the Year in 2023. Then, she transferred to the Wolverines, representing her home state for two seasons that took her from a defensive sparkplug off the bench to a senior veteran leader, standout defender on a national scale and an Elite Eight starter.
Quarles Daniels was second in the Big Ten with 2.4 steals per game in conference play, averaging 5.1 points, 5.4 rebounds, 1.9 ****** ists and 2.1 steals per game alongside a 1.7 ****** ist-to-turnover ratio in her final season for Michigan.
"Brooke, she's one of the hardest workers on the team, and she's given us literally everything she could possibly give to our team," junior guard Olivia Olson said March 30 following the Elite Eight loss. "With defense and just pressing all the time and just being a leader for our team, like she's really given everything. So it kind of just was like that, 'This is how you're going to go out. You're going to go out doing the same thing as you always have.' "
But now, thanks to an Aug. 18 ruling, Quarles Daniels isn't necessarily going out just yet. As part of a California lawsuit to gain extra eligibility, Quarles Daniels was among a group of Class of 2022 athletes who, via court ruling, were allowed to enter the transfer portal, entering the portal that same day, and committing to South Carolina on Aug. 28.
#going #brooke
The 5-foot-7 guard from Macomb, Mich. played two years at Oakland, averaging 12.8 points, 2.9 ****** ists and 2.2 steals per game while named to the All-Horizon League Second Team twice, as Freshman of the Year in 2023. Then, she transferred to the Wolverines, representing her home state for two seasons that took her from a defensive sparkplug off the bench to a senior veteran leader, standout defender on a national scale and an Elite Eight starter.
Quarles Daniels was second in the Big Ten with 2.4 steals per game in conference play, averaging 5.1 points, 5.4 rebounds, 1.9 ****** ists and 2.1 steals per game alongside a 1.7 ****** ist-to-turnover ratio in her final season for Michigan.
"Brooke, she's one of the hardest workers on the team, and she's given us literally everything she could possibly give to our team," junior guard Olivia Olson said March 30 following the Elite Eight loss. "With defense and just pressing all the time and just being a leader for our team, like she's really given everything. So it kind of just was like that, 'This is how you're going to go out. You're going to go out doing the same thing as you always have.' "
But now, thanks to an Aug. 18 ruling, Quarles Daniels isn't necessarily going out just yet. As part of a California lawsuit to gain extra eligibility, Quarles Daniels was among a group of Class of 2022 athletes who, via court ruling, were allowed to enter the transfer portal, entering the portal that same day, and committing to South Carolina on Aug. 28.
#going #brooke
10 days ago
Week 1 of the NFL season is on the horizon and we're about to enter the REAL start of the college football season this weekend. But it's not too early to peek at the talent expected to hear their names called in the 2027 NFL Draft.
Here is my first big board, ranking players Nos. 1-31 and a list of 10 to watch who could break into the mix later this season. Why 31 instead of 30? You'll see why I gave both of those ranked players, each quarterbacks, some shine.
Manning is an excellent athlete with size. He plays with a proper timing on plays when working from the pocket, but he can also throw consistently on the move and has the toughness and core strength to get any throw off no matter his platform or how muddy the pocket is or how he is getting hit. He has a good arm that he unlocks because of his creativity, ability to anticipate and willingness to push the football down the field. Manning's quick throwing motion unlocks underneath throws and he already has advanced feel in the pocket. He constantly keeps his eyes downfield, which allows him to get the ball off and avoid sacks, turning negative plays to positive, or even explosive ones.
His progression as a player was overlooked last year after an early-season loss to Ohio State and Texas having to gut out several wins, but his play, along with his tools, indicated a future No. 1 draft pick despite what looked like lackluster performances. There's a lot of hype, but he looks like he's worth it.
A force of nature at receiver, Smith has been a standout player and absurdly productive at every level of his career. He is strong, explosive, and has an excellent build that allows him to bounce off tackles and constantly eat up yards after the catch. His power as a player makes him dangerous on in-breakers that allow him to build up speed and get downhill in a hurry, and his speed and burst out of breaks make him dangerous. Even without pristine route refinement, Smith is still dominant. It's hard to compare any athlete to Julio Jones, and welp, here we are with Smith. At worst you're looking at a Josh Gordon-like player.
#player #like
Here is my first big board, ranking players Nos. 1-31 and a list of 10 to watch who could break into the mix later this season. Why 31 instead of 30? You'll see why I gave both of those ranked players, each quarterbacks, some shine.
Manning is an excellent athlete with size. He plays with a proper timing on plays when working from the pocket, but he can also throw consistently on the move and has the toughness and core strength to get any throw off no matter his platform or how muddy the pocket is or how he is getting hit. He has a good arm that he unlocks because of his creativity, ability to anticipate and willingness to push the football down the field. Manning's quick throwing motion unlocks underneath throws and he already has advanced feel in the pocket. He constantly keeps his eyes downfield, which allows him to get the ball off and avoid sacks, turning negative plays to positive, or even explosive ones.
His progression as a player was overlooked last year after an early-season loss to Ohio State and Texas having to gut out several wins, but his play, along with his tools, indicated a future No. 1 draft pick despite what looked like lackluster performances. There's a lot of hype, but he looks like he's worth it.
A force of nature at receiver, Smith has been a standout player and absurdly productive at every level of his career. He is strong, explosive, and has an excellent build that allows him to bounce off tackles and constantly eat up yards after the catch. His power as a player makes him dangerous on in-breakers that allow him to build up speed and get downhill in a hurry, and his speed and burst out of breaks make him dangerous. Even without pristine route refinement, Smith is still dominant. It's hard to compare any athlete to Julio Jones, and welp, here we are with Smith. At worst you're looking at a Josh Gordon-like player.
#player #like
11 days ago
IREN trades down 6% year to date while NBIS surged 150%, creating a contrarian entry if Roberts delivers Horizons 2-4 on schedule.
Customer prepayments funded 96% of IREN's Microsoft GPU capex, a capital-efficiency signal masking a $684M GAAP loss tied to scrapped mining hardware.
Nebius landed four contracts averaging over $1 billion each and holds $37 billion in obligations, but three customers generate 59% of its revenue.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Nebius Group didn't make the cut. Grab the names FREE today.
IREN Limited (NASDAQ:IREN) and Nebius Group (NASDAQ:NBIS) just reported earnings that read like two chapters of the same AI buildout. IREN is closing a Bitcoin-to-AI pivot. Nebius is stacking billion-dollar contracts on a full-stack cloud. One quarter looked painful. The other looked pristine.
#iren #nbis
Customer prepayments funded 96% of IREN's Microsoft GPU capex, a capital-efficiency signal masking a $684M GAAP loss tied to scrapped mining hardware.
Nebius landed four contracts averaging over $1 billion each and holds $37 billion in obligations, but three customers generate 59% of its revenue.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Nebius Group didn't make the cut. Grab the names FREE today.
IREN Limited (NASDAQ:IREN) and Nebius Group (NASDAQ:NBIS) just reported earnings that read like two chapters of the same AI buildout. IREN is closing a Bitcoin-to-AI pivot. Nebius is stacking billion-dollar contracts on a full-stack cloud. One quarter looked painful. The other looked pristine.
#iren #nbis
11 days ago
Barclays now expects the Federal Reserve to raise interest rates at its September and December meetings, reversing a prior forecast of no changes through the remainder of the year, after Federal Reserve Chair Kevin Warsh delivered a hawkish address at the annual Jackson Hole symposium last Friday, according to Reuters.
The Wall Street brokerage described Warsh's speech as "notably hawkish" and said it offered an implicit case for further tightening, according to Reuters. Each of the two projected increases would amount to 25 basis points. The Fed's benchmark federal funds rate currently stands at a target range of 3.5% to 3.75%.
Barclays did note that near-term monthly inflation prints are likely to look considerably cooler than the longer-horizon gauges Warsh cited, but warned that base effects would undercut any apparent improvement in those annual measures before December. Traders are **** igning a 60.4% probability to a September hike, CME Group's FedWatch tool showed.
Warsh's Jackson Hole address, his first keynote at the event as Fed chair, drew significant market attention as his clearest opportunity to fill what had been a deliberate communications void since he took office in May. Warsh told the symposium that policymakers would "have work to do" if they lacked confidence that inflation was returning to the Fed's 2% target. In his remarks, Warsh cast inflation as unacceptably elevated, judged prevailing financial conditions to be doing too little to restrain demand, and described the labor market as operating at or near full employment.
Warsh reinforced his opposition to providing explicit forward guidance, declining to spell out the conditions that would trigger a policy response. "I stand here today committed to a discipline, not to a decision," he said. He acknowledged that this summer's inflation readings came in better than expected but said they did not show meaningful improvement in underlying price trends. The 2-year Treasury yield climbed following the remarks, and traders raised the odds of a September rate increase.
#warsh #barclays
The Wall Street brokerage described Warsh's speech as "notably hawkish" and said it offered an implicit case for further tightening, according to Reuters. Each of the two projected increases would amount to 25 basis points. The Fed's benchmark federal funds rate currently stands at a target range of 3.5% to 3.75%.
Barclays did note that near-term monthly inflation prints are likely to look considerably cooler than the longer-horizon gauges Warsh cited, but warned that base effects would undercut any apparent improvement in those annual measures before December. Traders are **** igning a 60.4% probability to a September hike, CME Group's FedWatch tool showed.
Warsh's Jackson Hole address, his first keynote at the event as Fed chair, drew significant market attention as his clearest opportunity to fill what had been a deliberate communications void since he took office in May. Warsh told the symposium that policymakers would "have work to do" if they lacked confidence that inflation was returning to the Fed's 2% target. In his remarks, Warsh cast inflation as unacceptably elevated, judged prevailing financial conditions to be doing too little to restrain demand, and described the labor market as operating at or near full employment.
Warsh reinforced his opposition to providing explicit forward guidance, declining to spell out the conditions that would trigger a policy response. "I stand here today committed to a discipline, not to a decision," he said. He acknowledged that this summer's inflation readings came in better than expected but said they did not show meaningful improvement in underlying price trends. The 2-year Treasury yield climbed following the remarks, and traders raised the odds of a September rate increase.
#warsh #barclays
11 days ago
The recent scandal surrounding the Met Gala's decision to honor John Galliano with a Costume Institute retrospective at the Metropolitan Museum of Art has left many in a complicated position.
In late August 2026, the exhibition, ******* led "John Galliano: Horizons," was canceled. Galliano later issued a statement regarding the cancelation: "After much reflection and discussion with all those involved, I have decided, with great sadness, that it is best for the exhibition not to take place at this time. I remain fully accountable for the pain caused by my words in the past, particularly the hurt I caused to the Jewish and Asian communities, and I remain deeply sorry for it."
More from StyleCaster
Jeff Bezos Reportedly All But Confirmed to Back Out of Met Gala After Anna Wintour Saw Him as the 'Bankroll'-'Don't Want to Be Anywhere Near' It
Lauren Sánchez Reportedly 'Chased' for Her 'Money' at Met Gala After Report Anna Wintour Saw Jeff Bezos as the 'Bankroll'
#jeff #anna
In late August 2026, the exhibition, ******* led "John Galliano: Horizons," was canceled. Galliano later issued a statement regarding the cancelation: "After much reflection and discussion with all those involved, I have decided, with great sadness, that it is best for the exhibition not to take place at this time. I remain fully accountable for the pain caused by my words in the past, particularly the hurt I caused to the Jewish and Asian communities, and I remain deeply sorry for it."
More from StyleCaster
Jeff Bezos Reportedly All But Confirmed to Back Out of Met Gala After Anna Wintour Saw Him as the 'Bankroll'-'Don't Want to Be Anywhere Near' It
Lauren Sánchez Reportedly 'Chased' for Her 'Money' at Met Gala After Report Anna Wintour Saw Jeff Bezos as the 'Bankroll'
#jeff #anna
11 days ago
Cruzeiro and Atlético-MG to battle for a spot in the 2026 Copa Betano do Brasil semifinalsCredits: Gustavo Aleixo/Cruzeiro
Atlético-MG and Cruzeiro will decide a place in the 2026 Copa Betano do Brasil semifinals this Tuesday (1st). After a 1-1 draw in the first leg, the Minas Gerais rivals meet again tonight at 9 p.m. (Brasília time) at Arena MRV in Belo Horizonte, with live coverage on SporTV and Premiere.
If the teams draw again, the matchup will be decided on penalties, a real possibility given how evenly balanced the first meeting was.
On Wednesday (2nd), Vasco and Palmeiras will take the field looking to protect the advantage they built at home. This time, the challenge will be away from their own stadiums. After a 1-0 win, Vasco visits Vitória at Barradão in Salvador. At Vila Belmiro in Santos, Palmeiras, leading 3-0, faces Santos. Both matches will kick off at 9:30 p.m. (Brasília time) and will be available on TV Globo, SporTV, Premiere, and Amazon.
On Thursday (3rd), Arena do Grêmio in Porto Alegre hosts Grêmio vs. Internacional at 8 p.m. (Brasília time). Amazon will broadcast the Rio Grande do Sul derby. Gre-Nal finished scoreless in the first leg at Beira-Rio.
#arena #premiere
Atlético-MG and Cruzeiro will decide a place in the 2026 Copa Betano do Brasil semifinals this Tuesday (1st). After a 1-1 draw in the first leg, the Minas Gerais rivals meet again tonight at 9 p.m. (Brasília time) at Arena MRV in Belo Horizonte, with live coverage on SporTV and Premiere.
If the teams draw again, the matchup will be decided on penalties, a real possibility given how evenly balanced the first meeting was.
On Wednesday (2nd), Vasco and Palmeiras will take the field looking to protect the advantage they built at home. This time, the challenge will be away from their own stadiums. After a 1-0 win, Vasco visits Vitória at Barradão in Salvador. At Vila Belmiro in Santos, Palmeiras, leading 3-0, faces Santos. Both matches will kick off at 9:30 p.m. (Brasília time) and will be available on TV Globo, SporTV, Premiere, and Amazon.
On Thursday (3rd), Arena do Grêmio in Porto Alegre hosts Grêmio vs. Internacional at 8 p.m. (Brasília time). Amazon will broadcast the Rio Grande do Sul derby. Gre-Nal finished scoreless in the first leg at Beira-Rio.
#arena #premiere
12 days ago
In just a matter of days, Iowa will return to Kinnick Stadium to open its 2026 college football season against Northern Illinois.
With the season opener on the horizon, the Hawkeyes gave fans a glimpse of what things will look like on Saturday with the release of their Week 1 depth chart. The first depth chart of the season is always filled with interesting notes and eye-opening decisions. This year's edition is no different.
Iowa has some position battles coming down to the wire and this depth chart offered a first look at who has the pole position in those battles. What did we learn from the Hawkeyes' first depth chart of the 2026 season?
Here's a look at some takeaways from the Week 1 depth chart.
The biggest thing fans were curious to see was which quarterback was listed as the starter. Kirk Ferentz made it clear that the battle is still ongoing. He listed Hank Brown and Jeremy Hecklinski as the starter with the "OR" tag tying them together. It appears the starting quarterback battle will linger into Week 1, with both guys getting significant reps in the game.
#chart #first #hawkeyes #position
With the season opener on the horizon, the Hawkeyes gave fans a glimpse of what things will look like on Saturday with the release of their Week 1 depth chart. The first depth chart of the season is always filled with interesting notes and eye-opening decisions. This year's edition is no different.
Iowa has some position battles coming down to the wire and this depth chart offered a first look at who has the pole position in those battles. What did we learn from the Hawkeyes' first depth chart of the 2026 season?
Here's a look at some takeaways from the Week 1 depth chart.
The biggest thing fans were curious to see was which quarterback was listed as the starter. Kirk Ferentz made it clear that the battle is still ongoing. He listed Hank Brown and Jeremy Hecklinski as the starter with the "OR" tag tying them together. It appears the starting quarterback battle will linger into Week 1, with both guys getting significant reps in the game.
#chart #first #hawkeyes #position
12 days ago
John Galliano stepped down from the 2027 Met Gala after backlash over his past antisemitic and racist incidents
N.Y.C. Council Speaker Julie Menin advocated for Galliano's removal, citing the Met's public funding and the decision's implications
The Met is considering new themes and reportedly has two alternatives in place, a source tells PEOPLE
New York City Council Speaker Julie Menin is speaking out following John Galliano's exit from the 2027 Met Gala.
On Monday, Aug. 31, the Metropolitan Museum of Art Costume Institute and the designer announced the Met Gala and the museum's spring exhibition would no longer feature Galliano's work. The news came after the July 31 announcement that the 2027 theme would be "John Galliano: Horizons" faced backlash due to Galliano's past controversies.
#council #backlash #past #people
N.Y.C. Council Speaker Julie Menin advocated for Galliano's removal, citing the Met's public funding and the decision's implications
The Met is considering new themes and reportedly has two alternatives in place, a source tells PEOPLE
New York City Council Speaker Julie Menin is speaking out following John Galliano's exit from the 2027 Met Gala.
On Monday, Aug. 31, the Metropolitan Museum of Art Costume Institute and the designer announced the Met Gala and the museum's spring exhibition would no longer feature Galliano's work. The news came after the July 31 announcement that the 2027 theme would be "John Galliano: Horizons" faced backlash due to Galliano's past controversies.
#council #backlash #past #people
